Breaking Finance News

DZ BANK upgraded Gerresheimer (ETR:GXI) to Buy in a report released today.

DZ BANK has upgraded Gerresheimer(ETR:GXI) to Buy in a statement released on 9/16/2016.

On 9/13/2016, Hauck & Aufhäuser Privatbankiers KGaA released a statement for Gerresheimer(ETR:GXI) upped the target price from 0.00EUR to 80.00EUR. At the time, this indicated a possible upside of 0.10%.

Only yesterday Gerresheimer (ETR:GXI) traded 0.00% even at 74.47EUR. The company’s 50-day average is 0.00EUR and its 200-day average is 0.00EUR. With the last stock price close up 0.00% from the 200-day moving average, compared with the S&P 500 Index which has fallen -0.01% over the same time period. Trading volume was held steady, with 0 shares of GXI changing hands on par with the typical 0 shares..

See Chart Below:

Gerresheimer (ETR:GXI)

Gerresheimer has a one-year low of 0.00EUR and a one-year high of 0.00EUR. Gerresheimer’s market cap is presently 0.0 EUR.

General Company Details For Gerresheimer (ETR:GXI)

Gerresheimer AG is a Germany-based holding company and manufacturer of specialty products made of glass and plastic for the pharmaceutical and healthcare industries. The Company operates four business segments: Tubular Glass; Molded Glass; Plastic Systems, and Life Science Research. The Tubular Glass segment produces glass tubes converted to primary packaging. The Molded Glass segment produces glass primary packaging for pharmaceuticals, cosmetics products and specialty beverages and foods. The Plastic Systems segment produces customer-specific plastic systems fir pharmaceutics, diagnostics and medical technologies, and plastic containers mainly as primary packaging for pharmaceuticals and healthcare. The Life Science Research segment is focused primarily on specific tubular glass products and paste mould products for research and development in the pharmaceutical and life sciences industry and for general laboratory use and offers beakers, bottles and flasks, and among others.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.